DOI: 10.24996/ijs.2025.66.10.13





ISSN: 0067-2904

Effect of prodigiosin in biofilm formation of its producing bacterial isolates

Nagham Shakir Alattar, Heba Khaleel Tawfeeq, Jinan Mohammed Hasan*

Department of Biology, College of science, University of Baghdad, Baghdad, Iraq

Abstract

Serratia marcescens is gram negative bacteria, an opportunistic and nosocomial pathogen. Some strains possess the ability to produce a pigment called prodigiosin. While numerous studies have explored the antimicrobial properties of prodigiosin produced by S. marcescens against other microorganisms, the effect of prodigiosin on the producing S. marcescens isolates themselves remains unclear and warrants further investigation. Ten isolates of S. marcescens were isolated from 135 wound samples collected from some hospitals in Baghdad city. The isolates were cultured on selective media, identified by further biochemical tests and confirmed by VITEK2 compact system in (7.4%) isolation percentage. Four from the ten isolates were pigment producers. The ability of the bacterial isolates to form biofilm was assessed to the bacterial isolates by microtiter plate method; all isolates were biofilm producers. Prodigiosin's effect on the biofilm development of the producer isolates of S. marcescens was examined depending on incubation in different temperature (37 and 30°C) the results revealed reducing in their biofilm layers thickness. DNA was extracted from the four isolates to investigate the presence of four genes (flhD, fimC, bsmA and bsmB) related to the formation of biofilms, the results showed that the four isolates had all four genes (flhD, fimC, bsmA and bsmB). Prodigiosin effect on the expression of four genes was examined and the results showed an up regulation in gene expression in all isolates which indicates a relation between prodigiosin production and biofilm formation in S. marcescens.

Key words: Biofilm, Prodigiosin, Serratia marcescens, Wound infections, flhD gene

تأثير البروديجيوسين على تكوين الاغشية الحيوية في عزلاته المنتجة

نغم شاكر العطار, هبة خليل توفيق , جنان محمد حسن *

قسم علوم الحياة, كلية العلوم, جامعة بغداد, بغداد, العراق

الخلاصة

Serratia marcescens هي بكتيريا سالبة لصبغة الجرام، وهي من مسببات الأمراض الانتهازية والامراض المكتسبة من المستشفيات. تمتلك بعض السلالات القدرة على إنتاج صبغة تسمى البروديجيوسين. فيما تبحث العديد من الدراسات في الفعاليه الضد مايكروبية للبروديجيوسين من S. marcescens وخاصة نشاطها المضاد للميكروبات تجاه الكائنات الحية الدقيقة الأخرى، لكن تأثير البروديجيوسين في العزلات المنتجة لها لا يزال غير محدد ويتطلب اجراء بحوث اضافية . تم عزل عشر عزلات من S. marcescens من 135 عينة جروح تم جمعها من بعض المستشفيات في مدينة بغداد بعد زراعتها على أوساط انتقائية وتم تشخيصها من خلال اختبارات كيميائية حيوبة إضافية وتم تأكيدها بواسطة نظام VITEK2 بنسبة عزل (7.4٪). أربع من

^{*}Email: Ganan.hasan@sc.uobaghdad.edu.iq

العزلات العشر كانت منتجة للصبغة. تم تقييم تكوين الأغشية الحيوية للعزلات البكتيرية باستعمال طريقه لوحة المايكروتيتر.

وكانت جميع العزلات منتجة للأغشية الحيوية. تم دراسة تأثير البروديجيوسين على تطور الأغشية الحيوية لعزلات منتجه من S. marcescens اعتمادا على درجات حضانة مختلفة (37 و 30 درجة مئوية) وأظهرت النتائج انخفاض في سمك طبقات الأغشية الحيوية الخاصة بها. تم استخلاص الحمض النووي من العزلات الأربع للتحقق من وجود أربعة جينات (bsmB و bsmA، fimC ،flhD) المتعلقة بتكوين الأغشية الحيوية، أظهرت النتائج أن العزلات الأربع تحتوي على جميع الجينات الأربعة (fbsmB و bsmA، fimC ،flhD). تم فحص تأثير البروديجيوسين على التعبير الجيني لأربعة جينات وأظهرت النتائج زيادة في التعبير الجيني في جميع العزلات مما يدل على وجود علاقة بين إنتاج البروديجيوسين وتكوين الأغشية الحيوية في .marcescens

Introduction

Over the past four decades, *Serratia marcescens* has emerged as a notable healthcare-associated pathogen. There is a real cost associated with this organism incurs significant costs in terms of patient morbidity and antibiotic usage. This naturally occurring gram-negative bacillus can be found in water, soil, and at room temperature it produces a red pigment known as prodigiosin [1, 2]. This bacterium belongs to the family Enterobacteriaceae and is frequently linked to serious drug resistance. Since 1960, the number of *S. marcescens* infections has been rising, and the bacteria have been linked to a broad range of diseases, comprising sepsis and skin/soft tissue infections [3, 4], septicemia, wound, osteomyelitis, ocular, respiratory infections and endocarditis, as well as meningitis. Transmission occurs by direct contact with infected person [5, 6].

This pathogen is a DNase-producing, oxidase-negative bacterium capable of thrive in harsh environments [7, 8]. The bacteria secrete several enzymes, including hemolysin, proteases, nucleases, and lecithinases, which may are virulence factors contributing to its pathogenicity [9, 10]. A wider range of species are experiencing an increase in antibiotic resistance [11]. It has been documented to be effective against multiple classes of antimicrobials, such as aminoglycosides, polymyxins, and penicillins (first- and second-generation cephalosporins, carbapenem resistance mediated by β -lactamase). Due to its resistance to various antibiotics, treating infections caused *S. marcescens* can be challenging [12, 13]. Colored *S. marcescens* are strains that produce prodigiosin, which turns the bacteria red. Non-pigmented *S. marcescens*, on the other hand, do not have this characteristic [7, 14].

S. marcescens, a human pathogen, normally secretes prodigiosin, a red tripyrrole bacterial pigment, as a secondary metabolic product in the idiophase of bacteria. The three pyrrole rings that make up prodigiosin are A, B, and C. While the B and C rings are joined in a dipyrrin, the A and B rings are both bridged in a bipyrrole unit. A methylene bridge joins the monopyrrole moiety (C ring) to the methoxy bipyrrole moiety (A and B rings) [15, 16]. The bioactivity and color make this pigment a promising food colorant, antibacterial, and antifungal agent for use in textiles. Specifically, prodigiosin has demonstrated high apoptotic activity in many cancer cell lines both in vivo and in vitro, and low cytotoxicity in noncancerous cells; further investigation into this pigment may lead to the discovery of new anticancer medications [17, 18].

"A community of microorganisms attached to a suitable surface" is the definition of biofilm [19]. The extracellular polymeric substances (EPS), also known as the biofilm matrix, which make up roughly 90% of the biofilm's dry mass, regulates the formation and persistence of the biofilm. Microorganisms are shielded by their matrices from host immune defenses, chemical toxins, and protozoan grazers. Additionally, biofilm matrix, primarily composed of

polysaccharides, lipids, and nucleic acids, permits the diffusion of oxygen, nutrients, and waste products [20, 21]. *S. marcescens* depends on the quorum-sensing system to create biofilms by going through a series of unique steps that produce a highly porous, filamentous biofilm composed of clusters, filaments, and chains of cells [22]. An increase in population density activates a gene regulatory system called quorum sensing. *S. marcescens* produced quorum sensing via acyl homoserine lactone (AHL), which controls the formation of biofilms, swarming motility, and prodigiosin production [23]. It is common knowledge that quorum sensing (QS) contributes to bacterial pathogenicity, antibiotic resistance, and biofilm formation. Thus, QS inhibition may lower the chance of microbial pathogenicity in both local and systemic infections [24].

This study aims to: isolation and identify of *S. marcescens* from wound; detection the ability of isolates to produce prodigiosin, detection the ability of isolates to biofilm formation, and examined the effect of prodigiosin on *S. marcescens* biofilm.

Materials and Methods

- 1- **Bacterial isolates**: About 135 specimens were collected from wound infection by sterile cotton swab from different hospitals Al- Yarmouk Teaching Hospital, Al- Kindi Teaching Hospital, and Baghdad Teaching Hospitals at Baghdad city, Iraq. These specimens were cultured on MacConkey agar and Nutrient agar for colonial morphology at 37 °C for 18- 24 hrs. [25]. Further biochemical tests were performed and the diagnosis of the isolates was confirmed by Vitek-2 system.
- 2- **Prodigiosin production**: The non-lactose fermenter isolates, initially grown on MacConkey agar were sub-cultured on nutrient agar and incubated at 30 °C (the optimum temperature for prodigiosin production) for 18- 24 hrs in order to detect their ability to produce pigment. The pigmented isolates were used in the further tests [26].
- **3- Effect of prodigiosin on biofilm formation**: The capacity of the pigmented bacterial isolates to produce biofilm was determined using a microtiter plate assay [27]. Additionally, the effect of prodigiosin on biofilm formation was assessed depending on incubation in different temperatures (37 and 30 °C).

The bacterial broth culture was diluted 1:100 in Tryptic soy broth (TSB) and added with 1% glucose before being placed into the 200 μ l well, with the exception of the negative control well, which contains only TBS broth, in order to prepare the inoculum for biofilm formation. 200 μ l of TSB supplemented with 1% glucose and at least three copies of each strain were added to each well. The inoculation plate lid was placed, and the culture was grown aerobically for 24 to 30 hours at 37 °C in a static state. After three washes with sterile phosphate-buffered saline (PBS; pH 7.2), 150 μ l of 1% crystal violet was added and allowed to sit at room temperature for 15 minutes. The excess stain should then be rinsed off with tap water. To resolubilize the dye, 150 μ l of (95%) ethanol was added to each well. Each well that has been dyed crystal violet is measured for optical density (OD) at 630 nm using a microtiter-plate reader (GloMax, Promega, USA). The following categories can be used to group the strains: When OD \leq ODc, no biofilm is formed; when ODc \leq OD \leq 2× ODc, mild biofilm is formed; when 2× ODc \leq ODc and when 4× ODc \leq OD, strong biofilm is formed.

To assess the effect of prodigiosin on biofilm formation, the same protocol was followed. Two plates were incubated at 30°C and 37 °C for 24 hrs (taking into account providing the same conditions and additives for both plates so that the only variable is temperature). After incubation, all wells were washed, stained, and read.

4- Molecular methods:

- **1- Extraction of genomic DNA:** DNA was isolated from *S. marcescence*, employing EasyPure® Genomic DNA Kit (Transgene®/China), OneTaq® 2X Master Mix (NEB® (England) and Qubit™ dsDNA HS Assay Kit (Thermo Fisher®/USA) as directed by the manufacturer.
- **2- PCR Amplification:** The primers names (the source of all primers used in this study was Macrogen® (Korea)) for the four genes were detected *flhD*, *fimC*, *bsmA*, *bsmB* and *rpiU* as housekeeping gene and the sequence according to [28]. After being thawed at 4°C and vortexed to guarantee uniform contents, for a 100-mL PCR mixture, distributed maxima PCR premix (Intron, Korea) was made according to Table 1.

 Table 1: PCR reaction tubes were used to amplify DNA in a thermocycler PCR. Gradient PCR

was used to achieve the optimal PCR temperature and duration.

Name of primer	Sequence	Product size (pb)		
flhD	F:TTGCCACTTCCGCTTTAACG R: TCTTTTCTTCGTCGGGCTAG	155		
fimC	F:ACCAGCCGTTTCAACAACAA R: GTTTGTACGGTGCGATCTT	138		
bsmA	F:TAGTCCGCACACTCATCGC R: GATCTCCTGCGCCTGTGC	110		
bsmB	F:GCGGATGTGTATGCCTTCG R: GCCACGCATTTCTTCACTCA	180		
rpiU	F:AAATCGGCGTTCCTTTCGTC R: GCTTACGGTGGTGTTTACG	115		

- **3- Electrophoresis Following PCR:** Utilizing agarose gel electrophoresis, the outcomes were confirmed. PCR was used to extract all of the DNA parameters. One gram of agarose was added to a 100 ml beaker containing 1X TBE buffer in order to make a 2% agarose gel. The agarose was stained with Red Safe Nucleic Acid Stain (10 mg/ml). After mixing the agarose to avoid bubbles, the mixture was left to cool to a temperature of 50 to 60°C.
- **4- RNA purification protocol method:** The GENEzolTM TriRNA pure Kit from Bioer/ Japan was employed to extract the RNA from the *S. marcescence* isolates.
- **5- QRT-PCR, or quantitative real-time PCR:** RT-PCR should be performed in a nuclease-free environment. The steps of RNA sample preparation, reaction mixture assembly, PCR, and subsequent reaction analysis should be completed using RealMODTM Green qRT-PCR Mix in different locations.

The levels of expression were measured using relative quantitation. The difference in cycle thresholds (Δ CT) and fold changes between the treated groups and each gene's calibrators were calculated [29]. The expression of 16SrRNA was used to standardize the results as shown below:

Folding = $2-\Delta\Delta CT$

 $\Delta\Delta$ CT = Δ CT Treated - Δ CT Control

 Δ CT =CT gene - CT House Keeping gene

Results

1- **Bacterial isolates:** Ten isolates of *S. marcescens* were isolated from 135 wound samples collected from some hospitals (Al- Yarmouk Teaching Hospital, Al- Kindi Teaching Hospital, and Baghdad Teaching Hospitals) at Baghdad city, Iraq in Baghdad city after culturing on selective media and identified by further biochemical tests and confirmed by VITEK2 compact system in (7.4%) isolation percentage.

- **2- Prodigiosin production:** Four of the ten isolates were pigment producers (S6, S7, S8 and S9) at 30°C. (Optimum temperature for prodigiosin production).
- 3- **Effect of prodigiosin on biofilm formation:** Four of *S. marcescence* isolates were detected for biofilm formation (S6, S7, S8 and S9) by using two microtiter plates the first one incubated in 37°C (no pigment was produced) Table 2.

Table 2: The biofilm development optical density (OD) value for *S. marcescence* isolates without prodigiosin production

No. of isolates	OD1	OD2	OD3	Average	Result
S6	227	222	226	225	Moderate
S7	289	280	288	285	Strong
S8	257	259	258	258	Strong
S9	159	155	135	149	Moderate

Table 3: The biofilm development optical density (OD) value for *S. marcescence* isolates with prodigiosin production

1 0 1						
No. of isolates	OD1	OD2	OD3	Average	Result	
S6	373	370	369	370	Strong	
S7	400	399	397	398	Very Strong	
S8	418	422	425	421	Very Strong	
S9	290	287	285	287	Very Strong	

4- **Detection of biofilm genes:** five genes were detected *flhD*, *fimC*, *bsmA*, *bsmB* and *rpiU* for the four isolates of prodigiosin producing *S. marcescens* (S6, S7, S8 and S9). The results show that these isolates had the four genes, figure (1) and figure (2).



Figure 1: Gel electrophoresis of amplified PCR product of *fimC*, *bsmA*, *bsmB* for *Serratia marcescens*. 1.5% agarose gel electrophoresis stained with (Red Safe Nucleic Acid Stain (10 mg/ml), 100 v/m Amp for 75 min. TBE buffer (1X).




Figure 2: Gel electrophoresis of amplified PCR product of *flhD* and *rpiU* for *Serratia marcescens*. 1.5% agarose gel electrophoresis stained with (Red Safe Nucleic Acid Stain (10 mg/ml), 100 v/m Amp for 75 min. TBE buffer (1X).

5-Effect of prodigiosin on gene expression: To evaluate the effect of prodigiosin produced by of *S. marcescens* isolates on biofilm formation, gene expression of biofilm genes was detected with absence and presence of prodigiosin production, for *all* four genes. The results showed that an up regulation in gene expression of most genes in all isolates while there was a slight down regulation of *bsmB* and *fimC* in S9 and S8 isolates respectively (table 4).

Table 4: The effect of prodigiosin on gene expression of *flhD*, *fimC*, *bsmA*, *bsmB* genes in four isolates S6, S7, S8, S9.

Isolate	pre		Post			1.1.0:	Fold	D 1:	
code	rplU	bsmB	ΔCt	rplU	bsmB	ΔCt	ΔΔCt	change	Result
S6	23.64	25.57	1.93	24.6	26.45	1.85	-0.08	1.057018	Increase
S7	23.65	25.83	2.18	24.3	26.44	2.14	-0.04	1.0281138	Increase
S8	23.03	34.56	11.53	22.79	30.53	7.74	-3.79	13.832596	Increase
S9	23.11	31.6	8.49	22.96	31.57	8.61	0.12	0.9201877	Decrease
								4.2094788	
Isolate		pre Post				Fold			
code	rplU	flhD	ΔCt	rplU	flhD	ΔCt	ΔΔCt	change	Result
S6	23.64	24.48	0.84	24.6	24.81	0.21	-0.63	1.547565	Increase
S7	23.65	24.73	1.08	24.3	25.1	0.8	-0.28	1.2141949	Increase
S8	23.03	24.03	1	22.79	23.77	0.98	-0.02	1.0139595	Increase
S9	23.11	24	0.89	22.96	23.2	0.24	-0.65	1.5691682	Increase
								1.3362219	
Isolate	pre			Post		A A C:	Fold .	D 1	
code	rplU	fimC	ΔCt	rplU	fimC	ΔCt	ΔΔCt	change	Result
S6	23.64	25.06	1.42	24.6	25.83	1.23	-0.19	1.1407637	Increase
S7	23.65	25.39	1.74	24.3	25.8	1.5	-0.24	1.1809927	Increase
S8	23.03	24.68	1.65	22.79	24.5	1.71	0.06	0.9592641	Decrease
S9	23.11	24.76	1.65	22.96	24.5	1.54	-0.11	1.0792282	Increase
								1.0900622	

Discussion

Prodigiosin (C₂₀H₂₅N₃O) is a water- insoluble red pigment produced by *Serratia marcescens*, its name derived from "prodigiosine" a red extracted from *Bacillus prodigiosus* [30, 31]. Because the relevant puplication based on individual case report, guidelines for treatment of infection caused by *Serratia marcescens* do not exist [32]. One of the most urgent issues facing public health is bacterial resistance to antibiotics. Biofilms are hotspots to evolution which strong preference favors resistance to microbes, requiring new strategies for biofilm control [33, 34]. This sensitivity may be attributed to the structure of exopolysaccharides and a decrease in metabolic activity [35].

Both pigmented and non-pigmented strains of *S. marcescens* are extensively dispersed throughout environment. A number of non-pigmented varieties not possess any *pig* genes and in some cases, the entire gene cluster, according to the GeneBank databases sequence data [36, 37]. The findings suggest that *S. marcescens* inhibits high-cost processes, such as prodigiosin biosynthesis, but initiates amino acid metabolite and transport systems for additional resources, which support growth advantage in lab settings and the non-pigmented morphotypes exhibited a competitive growth advantage.

A viable strategy to increase the dissemination of antibiotics and other antimicrobial agents into the biofilm's base, encourage the removal of bacterial cells, and ultimately control infections is to disintegrate the biofilm matrices [38, 39]. Prodigiosin and related artificial substances, such as electron-rich pyrrolylpyrromethene structures, can be included in the group of substances that may disrupt biofilms [40, 41]. On a range of clinical (biomaterials, medical devices) and non-clinical (water membrane filters) related substrata, prodigiosin could be used as an antibacterial coating agent. As a potential treatment, prodigiosin aerosols may help break down eDNA and reduce the viscosity of phlegm in cystic fibrosis patients' lungs. One main offender that makes sputum more viscous and, as a result, seriously obstructs airways and inhibits easy breathing in cystic fibrosis patients is eDNA [20]. While numerous studies have explored the impact of prodigiosin as antimicrobial agent and alternative to antibiotics, but its role within the bacterial cell that produces it is still not completely known.

Mun'im et al. (2008) found that 398 swab samples from hospitals in Baghdad identified as *S. marcescens*. The detection was made based on bacterial cell culture, microscopical features, biochemical testing, and confirmation with api20E. In the nutrient broth, prodigiosin production was observed at 28°C. *S. marcescens* produces optimal pigments in peptoneglycerol broth at 30°C. It also forms colonies by producing prodigiosin on various culture media. [10]. The function of red pigment prodigiosin in the pathogenesis of *S. marcescens* is unclear, despite the fact that pigments produced by pathogenic microbes are typically considered to be significant virulence factors [42]. According to earlier reports, bacterial pigments are most likely connected to the pathogenic process [43].

In this study, we investigated whether prodigiosin pigment affects virulence factors or not. The formation of biofilm was chosen, and comparison was made between the thickness of the biofilm if it was produced or not depending on the temperature, as 30°C is considered the optimum temperature for prodigiosn production by bacteria [44]. The results revealed a significant difference in biofilm production between isolates incubated at 37°C and isolates incubated at 30°C, as biofilm production was greater at 30°C (optimum for prodigiosin production) than at 37°C (prodigiosin is not produced). The effect of the pigment on the expression of genes responsible for biofilm production in bacterial isolates was also studied. The results showed that the four bacterial isolates possessed all four genes (*flhD*, *fimC*, *bsmA*, *bsmB*). The expression of these genes was increased in all four isolates incubated in 30°C

except *bsmB* and *fimC* in S9 and S8 isolates respectively were slightly decreased. There are no previous studies that have investigated this aspect for comparison.

Conclusions

This study investigates the role of prodiogiocin on biofilm formation of *S. marcescence* isolated from wound infection. It was concluded that prodigiosin has an effect on the expression of the *flhD*, *fimC*, *bsmA*, *bsmB* genes involved in biofilm formation in *S. marcescence* which obviously increased i.e. an indication of the existence of a correlation between pigment production in bacteria and the thickness of their biofilm, and that means prodigiosin may has a role in *S. marcescence* pathogenicity by affecting biofilm, one of the important virulence factors in this bacterium. Further research is necessary to explore and clarify the role of prodigiosin in *Serratia marcescens* pathogenicity.

Acknowledgements

Not applicable.

Funding

No funding was received.

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors' contributions

The research's concept and design were aided by the authors, NSA and HKT. Every author who contributed to the study's methodology. HKT and NSA made contributions to the study's data collection and analysis. The manuscript was written in collaboration with JMH and NSA. After reading the final manuscript in its published form, each author gave their approval.

Ethics approval and consent to participate

The Iraqi Ministry of Health (Reference: CSEC/0823/0104) and the Ethics Committee of the University of Baghdad's Department of Biology approved the study's protocol. For each patient, written informed consent was obtained. The work was completed in compliance with the World Medical Association's code of ethics (Declaration of Helsinki).

Patient consent for publication

All of the study participants gave their written informed consent in order for their data to be published.

Competing interests

The authors declare that they have no competing interests.

References:

- [1] S. Cooney, S. O'Brien, C. Iversen, and S. Fanning, "Bacteria: Other Pathogenic Enterobacteriaceae Enterobacter and Other Genera". In: Editor(s): Encyclopedia of Food Safety. Yasmine Motarjemi(ed), Academic Press, pp. 433-441, 2014.
- [2] H. K. Abid," The Effect of Prodigiosin Extracted from *Serratia marcescens* on DNA Fragmentation of Human Peripheral Blood Lymphocytes Cells", *Iraqi Journal of Science*, vol. 57, no. (2C), pp. 1661–1666, 2023.
- [3] A. Hejazi and F. R. Falkiner, "Serratia marcescens", Journal of Medical Microbiology, vol.46, pp. 903-12, 1997.

- [4] S. R. Muhammad and I. J. Abed, "Evaluating of the Synergistic Effect of three Essential Oils on the Virulence Factors (resistance gene) of *Pseudomonas aeruginosa* and *Serratia fonticola* Isolated from Wounds", *Iraqi Journal of Science*, vol. 64, no. 10, pp. 4982–4999, 2023.
- [5] J. Buckle, "Infection, In: Clinical Aromatherapy "(3rd Ed). Churchill Livingstone, pp. 130-167, 2015.
- [6] M. J. Alwan, I. J. Lafta, and A. M. Hamzah, "Bacterial isolation from burn wound infections and studying their antimicrobial susceptibility", *Kufa Journal For Veterinary Medical Sciences*, vol. 2, no. 1, pp. 121–131, 2011.
- [7] K. Luttmann, V. R. Starnes, M. Haddad, and J. Duggan, "Serratia Marcescens, a Rare and Devastating Cause of Endocarditis: A Case Report and Review of the Literature", Cureus, vol. 14, no.6, pp. e25572, 2022.
- [8] A. Abbas and M. K. A. Al-Hassani, "Molecular Identification of Some Virulence Factors genes of *Serratia marcescens* Isolated From Clinical samples", *Iraqi Journal of Humanitarian Social and Scientific Research*, vol. 3, no. 9. pp, 1193-1201, 2023.
- [9] D. Golemi-Kotra, "Serratia, Edwardsiella and Morganella Infections", Editor(s): S.J. Enna, David B. Bylund, xPharm: The Comprehensive Pharmacology Reference, Elsevier, pp.1-6, 2008.
- [10] I. R. A. Mun'im, M. S. Hussin, and M. M. Kadum, "Study of prodigiosin and virulence factor producing by multi drug resistance *Serratia marcescens* isolated from some of Baghdad hospitals environment", *Al-Mustansiriyah Journal of Science*, vol. 19, no. 5, 2008.
- [11] R. M. S. Alkalidy and R. A. Aburesha, "Molecular detection of some virulence genes of Proteus mirabilis isolated from urinary tract infection in Iraq patients", *Iraqi Journal of Agricultural Science*, vol. 54, no. 3, pp. 409-415, 2023.
- [12] A. E. Dhamad," study of some antibiotics and NaCl affecting *Serratia marcescens* growth and product prodigiosin pigment", *Journal of Wassit For Science & Medicine*, vol. 2, no. 2, pp.41-54, 2009.
- [13] F. M. N. AL-Deen, "Evolution of Antibacterial Activity of Various Solvents Extracts of Annona Squamosa Fruit", *Iraqi Journal of Science*, vol. 58, no. 4C, pp. 2301–2308, 2018.
- [14] S. A. Al-Bakri and F. N. H. Al-Bederi, "Optimal Conditions Measured for Production of Prodigiosin from *Serratia marcescens* Bacteria Isolated from Different Sources", *Engineering and technology Journal*, vol. 34, no. 3B, pp.116-128, 2016.
- [15] T. A. Al-Awqati, D. Nabeel, A. Abduljabbar, and D. S. Al-Quaisi," *Serratia marcescens* Septicemia: An Outbreak in the Neonatal Unit of Al Yarmouk Teaching Hospital", *Iraqi Journal of Community*, vol. 28, no. 1, pp. 34-37, 2015.
- [16] A. Jasim, H. M. Jasim, and Dhahi," Optimum conditions for Prodigiosin production by *Serratia marcescens* S11", *Journal of Biotechnology Research Center*, vol. 5, no. 3, pp. 34-40, 2011
- [17] C. Lin, X. Jia, Y. Fang, L. Chen, H. Zhang, R. Lin, and J. Chen, "Enhanced production of prodigiosin by *Serratia marcescens* FZSF02 in the form of pigment pellets", *Electron Journal of Biotechnology*, vol.40, pp. 2019.
- [18] W. S. Al-wazni," Immunological effects of Biosurfactant extract from *Serratia marcescens* in mice", *Al-Kufa University Journal for Biology*, vol. 10, no. 3, pp. 147-159, 2018.
- [19] M. K. Abdrabaa and R. A. Aburesha," Gene Expression Evaluation of Intracellular Adhesins and Regulatory Genes among Biofilm Producing MRSA Isolates", *Iraqi Journal of Science*, vol. 64, no. 1, pp. 75-83, 2023.
- [20] Ö. Kimyon, T. Das, A. I. Ibugo, S. K. Kutty, K. K. Ho, J. Tebben, N. Kumar, and M. Manefield, "Serratia Secondary Metabolite Prodigiosin Inhibits Pseudomonas aeruginosa Biofilm Development by Producing Reactive Oxygen Species that Damage Biological Molecules", Front Microbiology, vol. 27, no. 7, pp. 972, 2016.
- [21] Z. H. Al-Fayyadh, A. M. Turki, and H. J. F. Al-Mathkhury," Glyceryl Trinitrate, a Vasodilating Drug Acts as an Antibiofilm Agent in *Serratia marcescens*", *Journal of Contemporary Medical Sciences*, vol. 9, no.3, pp. 175–178, 2023.
- [22] S. A. Rice, K. S. Koh, S. Y. Queck, M. Labbate, K. W. Lam, and S. Kjelleberg, "Biofilm formation and sloughing in *Serratia marcescens* are controlled by quorum sensing and nutrient cues", *Journal of Bacteriolology*, vol.187, no.10, pp.:3477-85, 2005.

- [23] T. Morohoshi, T. Shiono, K. Takidouchi, M. Kato, N. Kato, J. Kato, and T. Ikeda," Inhibition of quorum sensing in *Serratia marcescens* AS-1 by synthetic analogs of N-acylhomoserine lactone", *Applied of Environmental Microbiology*, vol.73,no.20, pp.:6339-44, 2007.
- [24] S. M. Khadar, K. P. Shunmugiah, and V. R. Arumugam, "Inhibition of quorum-sensing-dependent phenotypic expression in *Serratia marcescens* by marine sediment *Bacillus* spp. SS4", *Annals of Microbiology*, vol.62, pp. 443–447, 2012.
- [25] A. A. Hammoudi, "Association of Pathogenic Bacterial Isolates in Burn Wound Infections", *Medical Journal of Babylon*, vol. 11, no.1, pp. 52-57, 2014.
- [26] L. A. Yaaqoob, R. M. Abed, Z. K. Kamona, and M. F. Altaee, "Evaluation the ability of Titanium Oxide Nanoparticles to increase the production of Prodigiosin and Phenasine from *Serratia marcescence* and *Pseudomonas aeruginosa* respectively", *Iraqi Journal of Agricultural Sciences*, vol. 53, no. 3, pp. 496-504, 2022.
- [27] S. Stepanovic, D. Vukovic, V. Hola, G. Di Bonaventura, S. Djukic, I. Cirkovic, and F. F.Ruzicka, "Quantification of biofilm in microtiter plates: overview of testing conditions and practical recommendations for assessment of biofilm production by Staphylococci", *APMIS*, vol.115, no.8, pp. 891–899, 2007.
- [28] Z. Fekrirad, B. Gattali, and N. Kashef, "Qurum sensing- regulated function of *Serratia marcesens* are reduced by eugenol", *Iranian Journal of Microbiology*, vol.12, no.5, pp. 451-459, 2020.
- [29] K. J. Livak and T. D. Schmittgen," Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the $2-\Delta\Delta$ CT Method", *Methods*, vol. 25, no. 4, pp. 402-408, 2001.
- [30] Z. Ma, H. Xiao, H. Li, X. Lu, J. Yan, H. Nie, and Q. Yin, "Prodigiosin as an Antibiofilm Agent against the Bacterial Biofilm-Associated Infection of *Pseudomonas aeruginosa*", *Pathogens (Basel, Switzerland)*, vol. 13, no.2, pp.: 145, 2024.
- [31] R. P. Williams and W. R. Hear, "Prodigiosin". In: Gottlieb DS. P.D. (eds) Biosynthesis. Antibiotics. Springer, Berlin, Heidelberg, 1967.
- [32] Z. R. Zivkovic, M. Zaric, M. Sekulic, N. Zornic, J. Nesic, V. Rosic, T. Vulovic, M. Spasic, M. Vuleta, J. Jovanovic, D. Jovanovic, S. Jakovljevic, and P. Canovic, "Antimicrobial Treatment of *Serratia marcescens* Invasive Infections: Systematic Review", *Antibiotics (Basel)*, vol. 9, no.12, pp.367, 2023.
- [33] C. R. Kokare, S. Chakraborty, A. N. Khopade, and K. R. Mahadik, "Biofilm: importance and applications", *Indian Journal of Biotechnology*, vol. 8, pp. 159–168, 2009.
- [34] A. H. A. Alsalim, S. M. Shawkat, and M. I. Al khwaildy, "Bioactive Effect of Cinnamomum zealynicum bark Extracts on Some Locally Isolated Pathogenic Bacteria", *Iraqi Journal of Science*, vol. 57, no.1A, pp. 109–117, 2023.
- [35] B. N. Hoibya, A. B. T. Bjarnsholt, B. M. Givskov, S. Molin, and O. Ciofu, "Antibiotic resistance of bacterial biofilms", *International Journal of Antimicrobial Agents*, vol. 35, pp.322–332, 2023.
- [36] H. Magesh, A. Kumar, A. Alam, Priyam, U. Sekar, V. N. Sumantran, and R. Vaidyanathan, "Identification of natural compounds which inhibit biofilm formation in clinical isolates of *K. pneumoniae*", *Indian Journal of Experimental Biology*, vol. 51, pp. 764-772, 2013.
- [37] A. K. Harris, N. R. Williamson, H. Slater, A. Cox, S. Abbasi, I. Foulds, H. T. Simonsen, F. J. Leeper, and G. P. C. Salmond." The *Serratia* gene cluster encoding biosynthesis of the red antibiotic, prodigiosin, shows species-and strain-dependent genome context variation", *Microbiology*, vol. 150, pp. 3547–3560, 2004.
- [38] H. J. Fuchs, D. S. Borowitz, D. H. Christiansen, E. M. Morris, M. L. Nash, B. W. Ramsey, B. J. Rosenstein, A. L. Smith, M. E. Wohl, "Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group", *The New England Journal of Medicine*, vol. 331, pp. 637–642, 1994.
- [39] K. Heu, O. Romoli, J. C. Schönbeck, R. Ajenoe, Y., Epelboin, Y., V. Kircher, E. Houël, Y. Estevez and M. Gendrin, "The Effect of Secondary Metabolites Produced by *Serratia marcescens* on *Aedes aegypti* and Its Microbiota", *Frontiers in Microbiology*, vol.12, no. 645701, 2021.
- [40] Y. J. Oareed, M. Alshueli, M. Meteab, M. Alshammari, and G. H. Alwan, "Determination of parameters required to enhance the production of prodigiosin by *Serratia marcescens* with the antimicrobial activities Evaluation", *HIV Nursing*, vol. 22, no. 2, pp. 450-457, 2022.

- [41] T. DAS, P. K. Sharma, B. P. Krom, H. C. van der Mei, and H. J. Busscher, H.J," Role of eDNA on the adhesion forces between *Streptococcus* mutans and substratum surfaces: influence of ionic strength and substratum hydrophobicity", *Langmuir*, vol. 27, pp. 10113–10118, 2011.
- [42] W. Zhou, J. Li, J. Chen, X. Liu, T. Xiang, L. Zhang, and Y. J. Wan, "The red pigment prodigiosin is not an essential virulence factor in entomopathogenic *Serratia marcescens*", *Journal of Invertebrate Pathology*, vol. 136, pp. 92-94, 2016.
- [43] G. Y. Liu and V. Nizet, "Color me bad: microbial pigments as virulence factors", *Trends in Microbiology*, vol. 17, pp. 406–413, 2009.
- [44] S. S. Dhaife and N. S. Al-Attar, "Effect of prodigiosin on biofilm formation in clinically isolates of *Pseudomonas aeruginos"*, *Plant Archives*, vol. 21, no.1, pp. 826-834, 2021.